{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:56:10Z","timestamp":1790751370153,"version":"4.1.0"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thrombotic microangiopathy (TMA) complicating systemic lupus erythematosus (SLE) and lupus nephritis (LN) spans immune thrombotic thrombocytopenic purpura, anti-phospholipid-associated microangiopathy, secondary endothelial injury, and complement-amplified\/atypical hemolytic uremic syndrome (aHUS)-like phenotypes. The boundaries remain uncertain, and treatment evidence is dominated by selectively published cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this PROSPERO-registered systematic review (CRD420261409684), we searched PubMed, Embase, and Web of Science through to 17 March 2026, verified the source identity and eligibility, and performed a PubMed-only update through to 14 August 2026. We reconstructed patient-level reports by phenotype, competing mechanisms, complement-related evidence, treatment, and outcome. We included citable published abstracts when patient-level data were extractable but analyzed them as a lower-information stratum rather than as equivalent to full texts. Analyses were descriptive. We did not include China National Knowledge Infrastructure (CNKI) because no verifiable search record was available. One reviewer performed the screening, extraction, and appraisal. We report both as protocol deviations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 56 sources describing 78 patients: in total, 39 full-text sources\/61 patients and 17 published abstract sources\/17 patients. There were 56 female patients (71.8%), and the median age was 24.5 years. Source-adjudicated microangiopathic hemolysis, thrombocytopenia, acute kidney injury\/renal failure, strict TMA identified on kidney biopsy, and dialysis\/renal replacement therapy (RRT) were present in 71 (91.0%), 74 (94.9%), 67 (85.9%), 42 (53.8%), and 46 (59.0%), respectively. Low C3\/C4 levels were reported in 55 (70.5%), strict T2 complement evidence in 1 (1.3%), and index event terminal\/tissue activation in 6 (7.7%). Complement inhibitors were reported in 60 (76.9%) and renal and hematologic improvements in 49 (62.8%) and 65 (83.3%), respectively. Certainty was very low, and treatment comparisons were not estimable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SLE\/LN-associated TMA is heterogeneous, and complement may act as a driver, an amplifier, or an epiphenomenon. Case-based evidence supports rigorous mechanistic adjudication and biomarker-rich registries, but cannot establish incidence, prognosis, comparative efficacy, or universal treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261409684<\/jats:ext-link>\n                      , identifier CRD420261409684.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1940769","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:05:18Z","timestamp":1790748318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement-amplified thrombotic microangiopathy in systemic lupus erythematosus and lupus nephritis: a systematic review of 78 reported patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Sheng-Guang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujie","family":"You","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25528","article-title":"2024 American College of Rheumatology guideline for screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the Joint EULAR\/ERA-EDTA recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.409","article-title":"Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions","volume":"83","author":"Wu","year":"2013","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180773","article-title":"Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy","volume":"46","author":"Li","year":"2019","journal-title":"J Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1081942","article-title":"Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221106301","article-title":"Kidney thrombotic microangiopathy in lupus nephritis: impact on treatment and prognosis","volume":"31","author":"Massicotte-Azarniouch","year":"2022","journal-title":"Lupus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf326","article-title":"Renal thrombotic microangiopathy impairs renal function recovery in lupus nephritis","volume":"18","author":"Zhang","year":"2025","journal-title":"Clin Kidney J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","author":"van den Born","year":"2005","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","article-title":"Guidelines for the diagnosis and management of disseminated intravascular coagulation","volume":"145","author":"Levi","year":"2009","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes controversies conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902199","article-title":"A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs","volume":"184","author":"Denny","year":"2010","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47ra63","DOI":"10.1126\/scitranslmed.3001001","article-title":"Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"2","author":"Duffau","year":"2010","journal-title":"Sci Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"key":"B27","unstructured":"Clinical characteristics, treatment response, and renal outcomes of systemic lupus erythematosus\/lupus nephritis-associated atypical hemolytic uremic syndrome phenotype or complement-mediated thrombotic microangiopathy: a systematic review of case-based evidence\n          \n          \n            \n              Li\n              SG\n            \n            \n              Yu\n              R\n            \n            \n              Zhang\n              Y\n            \n          \n          Prospero\n          \n          2026"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2024.11.006","article-title":"De novo C3 glomerulonephritis of allograft associated with factor H autoantibody in a patient with systemic lupus erythematosus: a case report","volume":"57","author":"Patel","year":"2025","journal-title":"Transplant Proc"},{"key":"B29","volume-title":"JBI Critical Appraisal Checklist for Case Reports","year":"2020"},{"key":"B30","volume-title":"JBI Critical Appraisal Checklist for Case Series","year":"2020"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000045811","article-title":"Hemolytic-uremic syndrome superimposed on chronic lupus nephritis","volume":"86","author":"Al Shohaib","year":"2000","journal-title":"Nephron"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s004670050016","article-title":"Association of systemic lupus erythematosus and hemolytic uremic syndrome in a child","volume":"14","author":"Ogawa","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1159\/000065286","article-title":"A 12-year-old girl with hemolytic uremic syndrome as initial symptom of systemic lupus erythematosus and a literature review","volume":"22","author":"Kawasaki","year":"2002","journal-title":"Am J Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-001-0153-z","article-title":"Initial presentation of hemolytic uremic syndrome in a boy with systemic lupus erythematosus","volume":"21","author":"Tsao","year":"2002","journal-title":"Rheumatol Int"},{"key":"B37","article-title":"Systemic lupus erythematosus presenting as hemolytic uremic syndrome: a case report","volume":"55","author":"Rabbani","year":"2005","journal-title":"J Pak Med Assoc"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307077151","article-title":"Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura","volume":"16","author":"Hunt","year":"2007","journal-title":"Lupus"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-010-9754-3","article-title":"Atypical hemolytic uremic syndrome in the Tunisian population","volume":"43","author":"Leban","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02591.x","article-title":"Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange","volume":"42","author":"Samson","year":"2012","journal-title":"Intern Med J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00393-013-1255-1","article-title":"Role of complement-inhibition in thrombotic microangiopathy (TMA) associated with systemic lupus erythematosus (SLE): a case report","volume":"72","author":"Pierer","year":"2013","journal-title":"Z Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Med (Baltimore)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v4.i5.528","article-title":"Lupus-associated thrombotic thrombocytopenic purpura-like microangiopathy","volume":"4","author":"Blum","year":"2015","journal-title":"World J Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev307","article-title":"Eculizumab as rescue therapy in severe resistant lupus nephritis","volume":"54","author":"Pickering","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B48","first-page":"359A","article-title":"Homozygous deletion of CFHR3-CFHR1 as a cause for atypical hemolytic uremic syndrome in a patient with systemic lupus eyrthematosus","volume":"26","author":"Almaani","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000423","article-title":"Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus","volume":"22","author":"Bermea","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2016.6625","article-title":"Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab","volume":"8","author":"Raufi","year":"2016","journal-title":"Hematol Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2016.02.018","article-title":"An unexpected diagnostic course of systemic lupus erythematosus","volume":"58","author":"Taktak","year":"2016","journal-title":"Turk J Pediatr"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev371","article-title":"A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor","volume":"55","author":"Wig","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jim-d-15-00013.191","article-title":"Successful treatment of acute renal failure in patient with active lupus nephritis and atypical hemolytic uremic syndrome with C5a inhibitor, eculizumab","volume":"64","author":"Sarkissian","year":"2016","journal-title":"J Investig Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3823-2","article-title":"Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3: a case report and systematic review","volume":"36","author":"de Holanda","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B55","first-page":"159","article-title":"Novel PLG gene mutation with heterozygous CHFR1-R3 deletion in a patient with atypical hemolytic uremic syndrome and lupus nephritis","volume":"28","author":"Ali","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1425","article-title":"A case of patient with renal lupus with an initial presentation of hemolytic uremic syndrome triggered by streptococcal infection","volume":"6","author":"Attar","year":"2018","journal-title":"Clin Case Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0228-17","article-title":"A rare case of lupus nephritis presenting as thrombotic microangiopathy with diffuse pseudotubulization possibly caused by atypical hemolytic uremic syndrome","volume":"57","author":"Ono","year":"2018","journal-title":"Intern Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv"},{"key":"B59","article-title":"Eculizumab responsive atypical hemolytic uremic syndrome triggered by a multisystem lupus flare","volume":"29","author":"Syed","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B60","first-page":"802","article-title":"Concomitant atypical hemolytic uremic syndrome and lupus nephritis in a pregnant woman","volume":"29","author":"Bangaru","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.02.112","article-title":"Recurrent diffuse alveolar hemorrhage (DAH) from presumed acquired atypical uremic syndrome (AHUS) in a patient with active systemic lupus erythematosus (SLE)","volume":"71","author":"Gupta","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.15081","article-title":"Nearly fatal thrombotic microangiopathy complicating systemic lupus erythematosus: challenges in diagnosis and treatment","volume":"129","author":"Skoczy\u0144ska","year":"2019","journal-title":"Pol Arch Intern Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02293-2","article-title":"Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report","volume":"22","author":"Kim","year":"2021","journal-title":"BMC Nephrol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa474","article-title":"WT1 gene mutations in systemic lupus erythematosus with atypical haemolytic uremic syndrome","volume":"60","author":"Su","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000512227","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis treated with eculizumab: a case report","volume":"11","author":"Torres","year":"2021","journal-title":"Case Rep Nephrol Dial"},{"key":"B67","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1159\/000515882","article-title":"Anemia due to mycophenolate mofetil toxicity in a pediatric patient with lupus nephritis and atypical hemolytic uremic syndrome on hemodialysis","volume":"50","author":"Xie","year":"2021","journal-title":"Blood Purif"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1681\/asn.20213210s1473b","article-title":"Atypical hemolytic uremic syndrome and systemic lupus erythematosus-diabetes mellitus overlap: a challenging scenario","volume":"32","author":"Drexler","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104541","article-title":"Two concomitant thrombotic microangiopathies in the background of systemic lupus erythematosus: a case report","volume":"81","author":"AlGhobaishi","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25117","article-title":"Successful discontinuation of eculizumab in a pediatric patient with atypical hemolytic uremic syndrome and underlying systematic lupus erythematosus","volume":"14","author":"Alhamoud","year":"2022","journal-title":"Cureus"},{"key":"B71","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1007\/s11606-023-08226-z","article-title":"Atypical hemolytic uremic syndrome associated with lupus nephritis","volume":"38","author":"Lin","year":"2023","journal-title":"J Gen Intern Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20233411S1277c","article-title":"Lupus nephritis complicated by atypical hemolytic uremic syndrome and heterozygous deletion in CFHR1-CFHR3 successfully treated with ravulizumab","volume":"34","author":"Amin","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.07.3613","article-title":"Diffuse alveolar hemorrhage as a possible presentation of atypical hemolytic uremic syndrome in a patient with systemic lupus erythematosus","volume":"164","author":"Brill","year":"2023","journal-title":"Chest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05558-9","article-title":"Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature","volume":"44","author":"Smith","year":"2024","journal-title":"Rheumatol Int"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.02.1089","article-title":"WCN24-1884 thrombotic microangiopathy, systemic lupus erythematosus, and a vitamin B12 mutation: a cause of primary atypical hemolytic uremic syndrome","volume":"9","author":"D\u00edaz G\u00f3ngora","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-025-02425-z","article-title":"Iptacopan\/LNP023 and rituximab as rescue therapy in a patient with systemic lupus erythematosus-associated atypical haemolytic uraemic syndrome","volume":"38","author":"Benvenuti","year":"2025","journal-title":"J Nephrol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78989","article-title":"The critical importance of diagnosing atypical hemolytic uremic syndrome in postpartum renal dysfunction in a patient with systemic lupus erythematosus: a case report and comprehensive review","volume":"17","author":"Inatomi","year":"2025","journal-title":"Cureus"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2025-266485","article-title":"Sustained remission with eculizumab in refractory lupus nephritis with atypical haemolytic uraemic syndrome","volume":"18","author":"Thomson","year":"2025","journal-title":"BMJ Case Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.725","article-title":"Concurrent diffuse alveolar hemorrhage, atypical hemolytic uremic syndrome, and lupus nephritis in an SLE patient","volume":"158","author":"Khan","year":"2020","journal-title":"Chest"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00475-9","article-title":"Refractory secondary thrombotic microangiopathy with kidney injury associated with systemic lupus erythematosus in a pediatric patient","volume":"9","author":"Kaneda","year":"2020","journal-title":"CEN Case Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1681\/asn.20233411s1951b","article-title":"An unusual case of lupus-associated atypical hemolytic uremic syndrome presenting with diffuse alveolar hemorrhage and acute renal failure","volume":"34","author":"Theodoru","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/15563316241300474","article-title":"Systemic lupus erythematosus, thrombotic microangiopathy, and Purtscher-like retinopathy in a patient who experienced resolution with eculizumab treatment: a case report","volume":"22","author":"Baltaci","year":"2026","journal-title":"HSS J"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-025-07108-2","article-title":"Severe systemic lupus erythematosus with thrombotic microangiopathy: rescue therapy with pegcetacoplan","volume":"41","author":"Stirnkorb","year":"2026","journal-title":"Pediatr Nephrol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.100622","article-title":"Efficacy of plasma exchange in secondary thrombotic microangiopathy: a case report and literature review","volume":"18","author":"Fukunaga","year":"2026","journal-title":"Cureus"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.61882\/ijkd.3.03.9466","article-title":"Eculizumab in systemic lupus erythematosus complicated with thrombotic microangiopathy","volume":"20","author":"Nickavar","year":"2026","journal-title":"Iran J Kidney Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046412","article-title":"Systemic lupus erythematosus complicated by thrombotic microangiopathy with atypical HUS features: a case report","volume":"105","author":"Lin","year":"2026","journal-title":"Med (Baltimore)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.111765","article-title":"Severe class III lupus nephritis with concurrent thrombotic microangiopathy and suspected atypical hemolytic uremic syndrome requiring complement blockade: a complex multisystem presentation","volume":"18","author":"Pokharel","year":"2026","journal-title":"Cureus"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1791188","article-title":"Sirolimus application in patients with autoimmune-associated kidney diseases based on mTORC1 activation: a preliminary exploration and future perspectives","volume":"17","author":"Sun","year":"2026","journal-title":"Front Pharmacol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"hcag151","DOI":"10.1093\/qjmed\/hcag151","article-title":"Atypical haemolytic uraemic syndrome complicating lupus nephritis: dialysis independence and ANA seroreversion","author":"Yu","year":"2026","journal-title":"QJM"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.07.008","article-title":"Diagnostic utility of complement serology for atypical hemolytic uremic syndrome","volume":"93","author":"Sridharan","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis","volume":"8","author":"Risitano","year":"2021","journal-title":"Lancet Haematol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.11.015","article-title":"Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease","volume":"80","author":"Crew","year":"2020","journal-title":"J Infect"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101392","article-title":"Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome: the SETS aHUS trial","volume":"56","author":"Bryant","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag167","article-title":"Clinical phenotypes and etiologic subtypes of thrombotic microangiopathy in systemic lupus erythematosus","author":"Fortanell-Meza","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3881\/j.issn.1000-503X.16694","article-title":"Effects of different vascular lesions on the clinical, pathological, and prognostic features of lupus nephritis","volume":"48","author":"Qiao","year":"2026","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag031","article-title":"Early eculizumab treatment improves renal outcomes in pediatric lupus nephritis with thrombotic microangiopathy","volume":"41","author":"Yu","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1940769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:05:23Z","timestamp":1790748323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1940769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":107,"alternative-id":["10.3389\/fimmu.2026.1940769"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1940769","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1940769"}}